OTCBB: GMED
Sectors: Drugs
Biotechnology
Diagnostic Substances
Health Services
Medical Laboratories & Research
Potential portfolio matches: Alternative: Growth, Momentum, Quantitative, Theme
Highlights:
Our plan is to construct a comprehensive list of disease-causing genes so that we can predict with reasonable confidence what diseases a person may experience during their lifetime. By identifying the genes which cause disease within each person, we will be collecting the information required to potentially avoid disease in that person. While each individual is unique in genetic make-up, the vast majority of individuals within a given racial or ethnic denomination will have common genetic characteristics. Using this knowledge, GenoMed may identify a single gene that is responsible for a specific disease afflicting millions of people.
Scientific data that GenoMed's researchers and others have discovered through years of clinical studies and research has provided enough evidence to justify the Company's belief that it has identified a class of SNPs that appear to cause most common diseases. This means that: we believe that the vast majority of the competition is fishing in the wrong area of the genetic ocean, while we have evidence that indicates that we are fishing right where the most fish are located.
GenoMed is using a multidisciplinary approach to find disease-predisposition genes. We draw from the fields of molecular genetics, molecular and genetic epidemiology, genetic statistics, molecular evolution, bioinformatics, as well as other biomedical disciplines such as cell and molecular biology, pharmacology, biochemistry, physiology, and clinical medicine.
Summary:
Our goal is nothing short of a medical revolution: we aim to change the way medicine is practiced. Instead of waiting for symptoms to develop, we intend to diagnose disease before any signs are visible. Just as Microsoft brought us the Age of Personal Computing, GenoMed intends to be a leader in the Era of Genomic and Molecular Medicine.
News:
Jan 20, 2004 - SmartWire GenoMed Secures Additional Financing
Jan 15, 2004 - SmartWire GenoMed's Universal Approach to Viral Diseases Includes Avian Flu (Bird Flu) as well as SARS and Influenza A
Dec 26, 2003 - SmartWire GenoMed Seeks Volunteers for Novel Vitiligo Treatment
Dec 18, 2003 - SmartWire GenoMed's Universal Approach to Viral Diseases, Including the Flu and SARS, to be Tested by NIAID
Dec 8, 2003 - SmartWire GenoMed Announces Possible Universal Viral Antidote: Could Be First Line of Defense Against Viral Bioterrorism
Dec 4, 2003 - SmartWire GenoMed Launches Free Clinical Trial for Flu Patients
Dec 2, 2003 - SmartWire Latest Research Shows GenoMed's Approach May Be Ideal for SARS
Dec 1, 2003 - SmartWire GenoMed Ready to Aid World AIDS Effort
Nov 26, 2003 - SmartWire GenoMed tried to help Alonzo Mourning two years ago but could not get through to him
Nov 20, 2003 - SmartWire SARS Season Has Begun With First Probable Case In Taiwan; Public Needs to Learn About GenoMed's SARS Trial
. |
